stockrow
Friday 6 November 2026
Export XERS’s income statement to Excel — free account
Xeris Biopharma Holdings, Inc.
XERS Healthcare Drug Manufacturers Specialty & Generic
Xeris Biopharma Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $291.8 million, up 43.7% from fiscal 2024.
- Revenue
- +44.2%
- EPS
- +1,479.0%
- Free cash flow
- +93.2%
- Total debt
- −13.6%
Quarter to September 2026, against a year earlier
15.16
2.08
+15.90%
Follow XERS
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
7 | 6 | 8 | 8 |
+8 more TTM periods Free account |
| (27.11%) | 118.22% | (108.59%) | (6.96%) | ||
| (1.64%) | (4.60%) | 3.39% | 0.16% | ||
ROIC |
27.22% | 18.88% | 18.32% | 12.65% | |
Return on Tangible Assets |
(4.08%) | (19.07%) | 8.69% | 0.41% | |
Average Days of Receivables |
67.99 | 63.23 | 65.26 | 63.85 | |
Free Cash Flow per Share |
0.41 | 0.32 | 0.28 | 0.17 | |
Free Cash Flow |
73.65 | 55.67 | 47.52 | 27.93 | |
Capital Expenditures |
— | (0.94) | (1.01) | (0.70) | |
| Other line items | |||||
Cash ROIC |
19.93% | 15.27% | 13.73% | 8.09% | |
Accounts Receivable Turnover |
6.02 | 6.04 | 6.14 | 6.38 | |
Accounts Payable Turnover |
6.38 | 4.79 | 4.99 | 15.87 | |
Inventory Turnover |
0.64 | 0.61 | 0.70 | 0.73 | |
Average Days of Payables |
63.16 | 75.68 | 94.24 | 26.37 | |
Days of Inventory on Hand |
604.31 | 656.01 | 610.05 | 588.82 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
10.42% | 10.38% | 10.23% | 10.68% | |
Selling, General and Administrative Expense of Revenue |
61.31% | 62.05% | 60.82% | 62.49% | |
Share Based Compensation of Revenue |
8.49% | 8.38% | 7.01% | 7.66% | |
Interest Coverage |
1.70 | 1.30 | 1.25 | 0.86 | |
Operating CF/Net income |
(11.34) | (3.30) | 4.04 | 51.67 | |
Depreciation/Fixed assets |
0.00 | 3.37 | 3.21 | 3.25 | |
Capex/Depreciation |
— | (0.06) | (0.06) | (0.04) | |
Revenue per Share |
2.04 | 1.94 | 1.85 | 1.82 | |
Operating CF per Share |
0.41 | 0.33 | 0.28 | 0.18 | |
Capex per Share |
0.00 | (0.01) | (0.01) | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026